UNSPSC 51294002: Eprobemide

This classification denotes an antidepressant agent and antiarrhythmic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier URX5F7RDER. European Medicines Agency schedules Eprobemide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06585MIG. Eprobemide generally arises in the molecular formula C14H19CLN2O2.

UNSPSC 51294002 Eprobemide (Commodity) captures pharmaceutical and over-the-counter products procured by state and local health agencies, though the recent solicitation record shows limited alignment with the code's nominal scope. State and local governments buying under this code acquire naloxone (opioid antagonist) products, generic multi-source pharmaceuticals, and OTC products for community health programs, public health departments, and state pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances administering multi-jurisdiction pharmaceutical contracts (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These buyers solicit through competitive IFB and RFP processes, with some preliminary activity taking the form of Requests for Information to gather market intelligence before formal solicitation.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing vehicle extending eligibility to Oregon and other participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no formal award value specified. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline; the contract will run two years effective July 1, 2026, with a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation. The code shows modest recent volume but represents a viable target for manufacturers and distributors with FDA compliance, current Good Manufacturing Practices certification, and capability to serve state and local health benefit programs through authorized wholesalers.